Arthramid®, Leading Innovation in Animal Health

At Arthramid, we are committed to transforming the lives of animals and their owners through groundbreaking technology and innovative solutions. Our mission is to deliver safe, effective, and sustainable treatments that enhance the well-being and performance of animals worldwide.

 

INNOVATING ACROSS SPECIES WITH ONE HEALTH

At Contura, our commitment to innovation extends beyond animals to humans. The same cutting-edge technology used in Arthramid for veterinary care is also utilised in human medicine to treat osteoarthritis.

This One Health perspective underscores our dedication to creating solutions that benefit both animal and human health, driving advancements in global healthcare.

Arthramid equine

Precision Medicine

BUILT ON EXCELLENCE

Every Contura product is manufactured with the utmost precision in our state-of-the-art, GMP-certified facilities.

  • Stringent Quality Control: Each stage of production is monitored to ensure the highest quality and safety standards.
  • Patented Technology: Our proprietary ILX in-line cross-linking process sets our products apart, delivering superior performance and long-term benefits.
  • Global Compliance: Our manufacturing practices meet international regulatory requirements, ensuring trust and reliability across the globe.

Learn more about the Contura manufacturing process.

LEARN ABOUT CONTURA

Precision Manufacturing

Tour the Contura manufacturing facility in Denmark, Copenhagen
Watch video

Why Choose Contura?

  • Global Leader: Over 20 years of research and innovation in animal and human health.
  • Veterinarian-Trusted: Partnering with veterinary professionals worldwide to deliver effective treatments.
  • Commitment to Quality: Combining advanced technology with meticulous manufacturing processes for superior results.
  • Innovative Hydrogel Technology: Pioneering the use of injectable 2.5% polyacrylamide hydrogel (2.5 iPAAG) technology to revolutionise treatment for osteoarthritis in both animals and humans.
  • One Health Approach: Embracing the interconnected health of people, animals, and the environment, and advancing health solutions that benefit both veterinary and human medicine.

Arthramid - an OA treatment 20+ years in the making

For more than two decades, Contura has been researching, developing and manufacturing hydrogel products across multiple therapeutic areas to provide doctors and veterinarians with a proven long-lasting, non-degradable bio-scaffold injectable.

2000: PAAG is used in human clinical applications for soft tissue augmentation.

PAAG was used as a tissue filler in facial corrective surgery and breast augmentation with reportedly very good results.

2007: Arthramid is developed and tested in horses with OA (osteoarthritis).

Arthramid was developed as a treatment for joint lameness in horses, showing significant improvements in managing osteoarthritis

2008: Tnibar et al Publication

Tnibar et al tests Arthramid in an experimental OA model in goats and shows an improvement in joint capsule elasticity and ability to halt the progression of the disease seen on MRI.

2012: Janssen et al Publication

Janssen et al publishes an article on the use of Arthramid to treat distal interphalangeal joint lameness in 12 horses unresponsive to other therapies.

Arthramid becomes recognised for veterinary use to improve comfort in cases of degenerative joint diseases like osteoarthritis.

2015: Tnibar et al Publication

Tnibar et al publishes international multi-centre prospective study with long-term follow-up on the use of Arthramid in horses with OA.

This study demonstrates that Arthramid is a safe and effective treatment for osteoarthritis and joint lameness in horses and provides clinical evidence of its potential as a pioneering treatment for this debilitating disease.

2016-2019: Further studies (Bathe et al, de Clifford et al) are conducted to evaluate the efficacy and safety of Arthramid in horses with OA.

Multiple clinical studies, presentations and conference proceedings confirm the long-lasting and superior results of Arthramid compared to conventional treatments and show significant improvements in joint function and reduction in pain and inflammation.

2020: Arthramid is approved in New Zealand and Australia

Arthramid is approved in New Zealand and Australia as a Veterinary Medicinal Product after satisfying local regulators in clinical efficacy, safety, chemistry, manufacturing, and toxicology modules.

Studies validate the safety of Arthramid, showing no cytotoxic or neurotoxic effects and it was proven to be a stable and effective treatment for long-term management of osteoarthritis in horses.

2021: de Clifford and Lowe et al Publication

de Clifford and Lowe et al publish a double-blinded positive control study comparing the efficacy of 2.5% polyacrylamide hydrogel (PAAG) against triamcinolone acetonide (TA) and sodium hyaluronate (HA) in managing middle carpal joint lameness in racing Thoroughbreds.

The study confirmed PAAG’s superior efficacy and safety profile

2022: Contura becomes an educational partner for the AAEP

Contura becomes an educational partner for the AAEP, Tnibar publishes a review article on 2.5% PAAG, and further research focuses on understanding the precise therapeutic action of PAAG on the synovium, which is recognised as a critical factor in the pain of osteoarthritis.

This leads to improved treatment protocols and a better understanding of outcomes for equine patients

2024: Lowe et al Published

Lowe et al publishes histology and safety study confirming that Arthramid induces a typical low-level foreign body response that is predominantly macrophage-driven with no toxic effects or evidence of fibrosis or mineralisation. Integration of the gel is evident by 14 days, with no free gel remaining in the joint cavity.

2025 and beyond: Upcoming Research

Ongoing research, including with Colorado State University, continues to explore long-term safety in racing and performance horses, and a better understanding of the mechanism of action of PAAG in veterinary medicine, including investigating its use in canine OA and refining treatment protocols for optimal results.

Interested in talking to us and learning more?

Send us a message and we will get in touch

BOOK NOW
Vet pulling Arthramid box out of draw

Get The White Paper